Abstract
Human WRN, a RecQ helicase encoded by the Werner syndrome gene, is implicated in genome maintenance, including replication, recombination, excision repair and DNA damage response. These genetic processes and expression of WRN are concomitantly upregulated in many types of cancers. Therefore, targeted destruction of this helicase could be useful for elimination of cancer cells. Here, we provide a proof of concept for applying the external guide sequence (EGS) approach in directing an RNase P RNA to efficiently cleave the WRN mRNA in cultured human cell lines, thus abolishing translation and activity of this distinctive 3'-5' DNA helicase-nuclease. Remarkably, EGS-directed knockdown of WRN leads to severe inhibition of cell viability. Hence, further assessment of this targeting system could be beneficial for selective cancer therapies, particularly in the light of the recent improvements introduced into EGSs.
Original language | American English |
---|---|
Pages (from-to) | 572-580 |
Number of pages | 9 |
Journal | Biochimica et Biophysica Acta - Gene Regulatory Mechanisms |
Volume | 1859 |
Issue number | 4 |
DOIs | |
State | Published - 1 Apr 2016 |
Bibliographical note
Funding Information:We thank Dr. Tali Burstyn-Cohen (Hebrew University, Israel) for supporting the cell biology section of this research. We also thank Profs. Sidney Altman (Yale University, USA), Chang-En Yu (University of Washington, Seattle, Washington, USA) and Ram Reddy (Baylor College of Medicine, Houston, Texas, USA) for providing polyclonal antibodies directed against human RNase P, WRN cDNA and U6 snRNA gene, respectively. R. Serruya and N. Orlovetskie are grateful for doctoral fellowship support from the Hoffman Leadership and Responsibility Program and the Rudin Foundation, respectively. This research was supported by the Israel Cancer Association (grant # 2002-0048-B ) and the Israel Science Foundation (grant # 368/11 ).
Publisher Copyright:
© 2016 Elsevier B.V.
Keywords
- External guide sequence
- RNase P RNA
- WRN helicase, selective cancer therapy
- Werner syndrome